ASH: CAR T-Cell Therapy Promising for Relapsed/Refractory iNHL
Phase 2 study reveals high objective response rate for CAR T-cell therapy in patients with follicular lymphoma, marginal zone lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.